Therapy News and Research

RSS

STJ inaugurates Advanced Technology Center for physicians in Beijing

St. Jude Medical, Inc., a global medical device company, today celebrated the grand opening of the St. Jude Medical Advanced Technology Center Asia Pacific, located in Beijing, China.

22 Mar 2011

BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced that a clinical trial -- known as study 024 -- of its investigational compound ipilimumab has met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.

22 Mar 2011

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Benitec Limited (ASX:BLT), a company involved in RNA-based gene silencing for human therapeutics, announced that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec’s DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

21 Mar 2011

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

"The Canadian Association of Radiation Oncology (http://www.caro-acro.ca) is the voice for specialists in Canada who treat patients' cancer with radiation. In that capacity," explains Dr. Matthew Parliament, president of CARO-ACRO, "we work with proven, controlled, targeted application of various forms of radiation therapy to treat and cure cancer."

21 Mar 2011

Curemark reaches targeted enrollment in CM-AT Phase III clinical trials for autism

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the company has completed its targeted enrollment of Phase III clinical trials for CM-AT, its autism treatment.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Synageva BioPharma closes $25 million private equity financing

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today the closing of a $25 million private equity financing.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

Advanced Cell Technology reduces 2010 debt to less than $1 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today 2010 year-end results for the period ended December 31, 2010. The Company utilized $8.8 million in cash for operations during the year, compared to $5.1 million in the year-earlier period.

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

A team of scientists from Princess Margaret Hospital have created an organic nanoparticle that is completely non-toxic, biodegradable and nimble in the way it uses light and heat to treat cancer and deliver drugs.

21 Mar 2011

More opportunities to develop therapies for protein misfolding

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought.

21 Mar 2011

$CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma$

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Cell Therapeutics, Inc. today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL").

21 Mar 2011

Asthma an diabetes go hand in hand: Research

A new study has found that people with asthma may have a higher risk of developing diabetes and heart disease. The study looked at the relationship between asthma and four other inflammatory conditions.

21 Mar 2011

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

19 Mar 2011

Insight into hereditary diseases

Hereditary diseases such as epilepsy or various coordination disorders may be caused by changes in nerve cells of the cerebellum, which do not set in until after birth. This is reported by Bochum's neuroscientists in the Journal of Neuroscience.

19 Mar 2011

Are newer prostate cancer treatments — now gaining popularity — worth the extra cost?

Newer technologies for treating prostate cancer have surged in popularity in the last decade — and they have come with a hefty price tag, according to a report published this week.

19 Mar 2011

ACRIN, ECOG, NCI intent to merge their clinical cancer research programs

The American College of Radiology's Imaging Network and the Eastern Cooperative Oncology Group, National Cancer Institute Clinical Trials Cooperative Group members, today announced their intent to merge their clinical cancer research programs.

19 Mar 2011

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced the publication of results from a randomized-controlled clinical trial of the bulking agent, NASHA DX, a dextranomer suspended in stabilized, which was injected into the submucosa of the anal canal in patients with fecal incontinence.

19 Mar 2011

Therapy News and Research

STJ inaugurates Advanced Technology Center for physicians in Beijing

BMY's ipilimumab Phase III study against metastatic melanoma meets primary endpoint

Second US trial in HIV/AIDS lymphoma patients using Benitec’s ddRNAi technology

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

Curemark reaches targeted enrollment in CM-AT Phase III clinical trials for autism

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Synageva BioPharma closes $25 million private equity financing

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

Advanced Cell Technology reduces 2010 debt to less than $1 million

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Organic, non-toxic, biodegradable nanoparticle uses light and heat to treat cancer

More opportunities to develop therapies for protein misfolding

CTI commences pixantrone PIX-R trial in relapsed/refractory diffuse large B-cell lymphoma

Asthma an diabetes go hand in hand: Research

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

Insight into hereditary diseases

Are newer prostate cancer treatments — now gaining popularity — worth the extra cost?

ACRIN, ECOG, NCI intent to merge their clinical cancer research programs

The Lancet publishes Oceana's Solesta injectable gel study results against fecal incontinence

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News